Clinical Trial Search Results

Filter Results

Age group

Category

Primary purpose

Study type

Location

Search results

You can use the filters to refine your search.

Displaying 1 - 20 of 47

Open Actively Recruiting

New Moms Mood Tracking & Wellbeing

New moms can be at risk for perinatal depression (PND). The New Moms Mood Tracking and Wellbeing study is investigating mood changes, risk factors for depression and anxiety and treatment response around the time of delivery. Participants will be asked to complete three sets of online surveys between week 28 gestation and week 20 after delivery, in addition to downloading an app to collect data using their smartphone sensors and brief symptom surveys every other week. Women with elevated symptoms can participate in treatment. Women will be randomized to one of two conditions - Perinatal Psychiatric Care or Screening and Treatment for Anxiety and Depression (STAND). In Perinatal Psychiatric Care, participants will receive appointments with psychiatry clinicians. In STAND, participants will be further allocated to Online therapy with Coaching or Clinical Care, which includes both psychotherapy and psychiatry appointments. Treatment can last up to 6 months and there will be treatment related assessments for the duration of the 6 months, in addition to brief symptom surveys on a regular basis. Therefore, participation can last between 24 and 52 weeks, as both time of delivery and treatment enrollment timepoint cannot be scheduled in advance.

Phase: N/A
Primary Purpose: Treatment
Gender: Female
Age Group: Adults
Contact: INNA ARNAUDOVA
Investigator:
MICHELLE CRASKE
Open Actively Recruiting

Responsive Neurostimulation for Post-Traumatic Stress Disorder

Post-traumatic stress disorder (PTSD) refractory to treatment is marked by failure of fear extinction and its biological substrate, amygdala reactivity to trauma reminders. Decades of research have clarified the neuronal mechanisms coordinating fear extinction and consolidation. Fear cells and extinction cells in the basolateral amygdala (BLA) alter their firing rate based on the nature of the stimulus and the influence from the medial prefrontal cortex (mPFC) and the ventral hippocampus (vHPC). Together, the BLA, mPFC, and the vHPC form an anxiety-processing network where the BLA links stimulus to emotion, the vHPC provides memory context, and the mPFC coordinates extinction or consolidation. Local field potential (LFP) recordings from the BLA have revealed specific signals that correspond to an enhanced fear state. Previous studies have shown that neuromodulation of the BLA can promote extinction in a rodent model and in a treatment-refractory PTSD patient. This action is likely carried by disrupting fear signals within the BLA; however, continuous neurostimulation may also disrupt normal function of the amygdala. The present application proposes to investigate the use of Responsive Neurostimulation (RNS, Neuropace) in six (6) veterans suffering from severe treatment-resistant PTSD. This dual-activity device will allow us to chronically record LFPs from the BLA under specific conditions such as fear conditioning, exposure to trauma reminders, and emotional memory encoding and retrieval. In addition, the neural activity will be captured during real-life symptoms of flashback and nightmares. These recordings will provide the specific electrophysiological biomarkers of hypervigilance and re-experiencing. The device will then be programmed to detect and treat these biomarkers with a pre-determined electrical pulse. The patients will be followed prospectively using psychological scales but also with functional neuroimaging and electroencephalograms. These modalities will be used to determine the extent of circuit engagement as a result of the therapy. By approaching PTSD from a fear processing mechanism perspective, our project will serve as a proof of concept for other circuit-based therapies in psychiatry. This proposal is a multi-departmental effort involving 11 investigators across 7 departments and requires a close collaboration between clinical and basic scientists. As a result, the findings underlying chronic recordings will bridge the basic science results from fear conditioning research to clinical neural processes in PTSD patients.

Phase: Early Phase 1
Primary Purpose: Treatment
Gender: Male
Age Group: Adults
Open Actively Recruiting

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP).

This is a prospective, multi-center, 2-arm randomized, double-blind, parallel-group, sham-controlled study. The study will include the following stages: 1. Screening, Eligibility evaluation and Randomization to Relivion®DP vs. Sham control (1:1 randomization) (Baseline - Day 0). 2. Daily treatment period: Active/Sham (Group A/B) treatment protocol (Baseline to end of 8 weeks). 3. Open label phase: Active treatment period of additional 8 weeks. After completion of the open label period the subject's participation in the study will be over.

Phase: N/A
Primary Purpose: Treatment
Gender: All
Contact: Nikita Vincecruz
Open Actively Recruiting

Effects of Propranolol on Brain and Behavioral Markers of Sensory Over-Responsivity

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Children
Contact: KAITLIN CUMMINGS
Investigator:
SHULAMITE GREEN
Open Actively Recruiting

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

This study will be conducted to evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with Autism Spectrum Disorder (ASD).

Phase: Phase 2
Primary Purpose: Treatment
Gender: All
Contact: JENNIFER COWEN
Open Actively Recruiting

Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment

The purpose of this study is to see if stimulation of the brain can improve memory. The investigators will use a device called transcranial magnetic stimulation that can stimulate and activate a specific part of the brain that is important for memory. The study will enroll MCI subjects who will be randomly assigned to receive active or sham brain stimulation. 'Blinded' or 'sham-controlled' means that the subject will not know whether the treatment they receive is the active treatment or the non-active stimulation. In the 'sham' condition, the stimulator will turn on but will not actually be stimulating the target brain region.

Phase: N/A
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Investigator:
Nanthia Suthana
Open Actively Recruiting

A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome

This is a Phase I, multicenter, non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study using IT administration to investigate the safety, tolerability, PK and PD of RO7248824 in participants with AS.

Two linked sets of dose escalation cohorts are planned based on two different age groups, namely participants with AS aged ≥ 5 to ≤ 12 years in cohorts A1 to A4 (with at least 2 participants ≤ 8 years old in each cohort) and AS participants aged ≥ 1 to ≤ 4 years in cohorts B1 to B5. The two sets of cohorts will be run in parallel, with each cohort A1-A4 preceding and gating the linked cohort B1-B5 (e.g., A1 precedes B1).

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: LOGAN SHURTZ
Open Actively Recruiting

Analgesic and Subjective Effects of Terpenes

The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.

Phase: Phase I
Primary Purpose: Basic Science
Gender: All
Age Group: Adults
Contact: MARY OLSON
Investigator:
Ziva Cooper
Open Actively Recruiting

Cannabis Effects as a Function of Sex (CanSex)

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women

Phase: Phase I
Primary Purpose: Basic Science
Gender: All
Age Group: Adults
Contact: MARY OLSON
Investigator:
Ziva Cooper
Open Actively Recruiting

Multisite Study of Adolescent & Adult Transitions

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Investigator:
MIRELLA DAPRETTO
Open Actively Recruiting

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.

Phase: Phase IV
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Fe Asuan
Investigator:
Kenneth Subotnik
Open Actively Recruiting

Oxidative Stress Markers in Individuals with Hair Pulling Disorder

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Phase: Pilot/Feasibility
Age Group: Adults
Contact: NANCY LE
Open Actively Recruiting

Cannabidiol as Adjunctive Treatment for Opioid Use Disorder

This research aims to determine the effects and safety of cannabidiol (CBD) as an adjunctive therapy for patients, who have Opioid Use Disorder and are taking buprenorphine + naloxone. Buprenorphine + naloxone is an approved treatment for Opioid Use Disorder, but relapse to opioid misuse is common among patients who receive this treatment. Finding an adjunctive treatment that does not have abuse liability and reduces relapse for these patients would be helpful.

Investigators will recruit participants from the Tarzana Treatment Center in Los Angeles. They will be receiving buprenorphine + naloxone as part of residential therapy. Potential participants who pass initial screening and wish to continue in the study will provide written, informed consent and will complete a screening evaluation, including blood and urine tests, questionnaires about their mood, medical, psychiatric and drug use history and a physical exam. Sixty participants who meet all eligibility criteria will be invited to complete baseline assessments (blood and urine tests, questionnaires), and will be assigned randomly to receive CBD or placebo in each of three cohorts, corresponding to two dose groups of 20 participants per cohort (CBD 600, 1200mg/day). Within each cohort, 20 participants will receive CBD and 10 will receive placebo. The cohorts will be studied in ascending dose order to ensure safety. Each day, participants will take the study medication twice daily under supervision. Questionnaires on opioid craving, withdrawal, and mood symptoms will be administered daily during the treatment period. Cue-induced craving will be assessed at 3 timepoints (days 0, 7 and 28). PK samples will be assessed at multiple time-points during the study. After the 28-day intervention, participants will complete questionnaires and undergo urine drug tests in weekly follow-up visits (days 29-56). PK samples will be assessed at multiple time-points during the follow-up period. The study will last ~9 weeks, comprising three periods: a screening period (~7 days during which participants are stabilized on buprenorphine + naloxone in residential treatment at Tarzana Treatment Center), a treatment period (4 weeks when study CBD or placebo is administered at UCLA), and a follow-up period (4 weeks after termination of the test intervention).

Phase: Phase I/II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Edythe London
Investigator:
Edythe London
Open Actively Recruiting

Decision-making in OCD: an fMRI/TMS Study

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: REZA TADAYON-NEJAD
Open Actively Recruiting

Infant Attachment Security and Perinatal Depression: The Effect of SSRI Treatment on Salivary Oxytocin Levels and Early Mother-Infant Interactions

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: All
Contact: NICOLE MCDONALD
Open Actively Recruiting

Genetic Factors of Bone Loss in Older Adults Taking Antidepressants

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: RAQUEL HERNANDEZ SOTOMAYOR
Open Actively Recruiting

Technology Enhanced Family Treatment

The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application called MyCoachConnect (MCC). In adolescents with mood instability who have a parent with bipolar or major depressive disorder, clinicians in community clinics will conduct FFT sessions (consisting of psychoeducation and family skills training) supplemented by weekly MCC "real time" assessments of moods and family relationships; based on results of these assessments and the family's progress in treatment, clinicians will then push personalized informational and coaching alerts regarding the practice of communication and problem-solving skills. The investigators hypothesize that the augmented version of FFT (FFT-MCC) will be more effective than FFT without coaching/informational alerts in altering treatment targets and in stabilizing youths' mood symptoms and quality of life.

Phase: Phase I
Primary Purpose: Treatment
Gender: All
Age Group: All
Contact: DANIELLE DENENNY
Open Actively Recruiting

Randomized Controlled Trial of Standard ERP and OC-Go

Phase II of this study will examine the efficacy of the OC-Go application via a randomized controlled trial comparing standard exposure and response prevention (ERP) treatment for pediatric obsessive compulsive disorder (OCD) to exposure/response prevention (ERP) augmented with OC-Go. A cross-over design will be implemented for these 12 sessions of treatment, in which participants that were randomized to standard ERP will receive OC-Go augmented ERP for the second half of treatment, and vice versa. Efficacy will be investigated in a sample of 32 children with OCD.

Phase: N/A
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: KATHERINE DELGADILLO-SOTO
Open Actively Recruiting

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Open Actively Recruiting

An Initial Case Series of Intranasal Glutathione for Women with Hair Pulling Disorder

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: NANCY LE